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An Interview
With Dr. Lewis Thomas

Ttie Road
CO

n

long the tile corridor of the sixth floor of
Memorial Sloan-Kettering Cancer Center in
New York City stand cylinders of compressed
gas, portable trays on wheels, metal stands holding
plastic jugs of colorless liquids, and cabinets filled
with beakers, glasses, and boxes of chemicals. One
passes labs with glass tubing and glowing Bunsen
burners, refrigerated labs behind metal doors, and
white -coated men and women. At the end of the hall
is the office of Dr. Lewis Thomas, chancellor of the
institute as well as the author of such renowned
books as The Lives of a Cell, The Medusa and the
Snail, and, most recently, The Youngest Science, Notes
of a Medicine-Watcher.
Dr. Thomas is a soft-spoken scientist whose
outward calm belies his invigorating mind. As he
discusses issues facing the scientific and business
communities, he chooses to focus on what he calls the
"intellectual connections" between the two fields,
particularly the shared concerns about basic and
applied research.
His thoughts come slowly, softly. His fingers move
gently, cupping a cigarette, twirling tortoise shell
glasses, cradling his j a w as he speaks. The following
is an edited version of a recent conversation.
You have said that you are not sure that the
term "high technology" could be applied to the
biomedical field. Would you care to explain?
What I meant is that I don't regard machinery, such
as a CAT scanner or the artificial heart, as representing high technology. I think today's version of high
technology in the biomedical field is the working out
of techniques for manipulating DNA in vivo. Recombinant DNA is an advance that I would regard as the
greatest thing that has ever happened in biological
science. It is now possible for cell biologists and
immunologists and molecular geneticists to get
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answers that were inconceivable just a few years ago.
I think that when historians one day write about the
biological revolution, they'll date it in the past decade.
The significance of recombinant DNA technology is
that we can now begin to look at events not just
inside the cell but inside the intricate machinery of
these cells, and this means to me that we ought to be
able to explore disease mechanisms in a way we've
never been able to do before. This is why I'm so
optimistic about our being able to do something
decisive with the problem of cancer in some sort of
real time. The work is moving very fast, and the
investigators who are doing this work are extremely
enthusiastic, highly competent, and pretty sure that
before long they're going to understand what goes on
at a deep level in cancer. And when that happens, it is
likely that we will be able to devise either pharmacological or immunological approaches that we would
not have been able to come up with otherwise.
So the great need in medicine is for more basic
biomedical research, and I would like to talk about
something fascinating that is happening today in
this field.
What do you see taking

place?

Well, there are new connections being made between
industrial science and academic science. It used to be
that industrial science—or applied science—was
targeted toward a product, while what -went on in the
university world was largely basic science that was
aimed at acquiring an understanding of the mechanisms in nature. And there was no connection
between those two communities. A few decades ago,
this changed in the physical sciences, as institutions
like MIT and Cal-Tech began working with the
industrial world, and some major corporations began

investing in basic science in the universities. But this
didn't happen in biomedical science until recently.

So you are comfortable
financial
resources.

Why did it happen in the other fields
medicine?

Yes, but I'm worried, too. I'm worried that sooner or
later we may start neglecting some fields of science. I
sense a belief in Washington that there is not enough
money to do basic research across the board in
biology, in physics, in chemistry, and so we should
support these fields which look as though they have
some promise for the 1990s. I see a great danger in
committees sitting down and trying to figure out
what's going to be important 10 or 20 years from
now. It would never have crossed anyone's mind in
the 1960s what we are able to do today in manipulating genes, of inserting genes from one kind of cell
into a different cell. What we had was a lot of
research in molecular biology being done just because
it was fascinating to young scientists.

and not in

I think it became quite clear after World War II that
there were problems of deep concern to the corporate
world which could be solved only by making use of
the basic science information being generated in the
university laboratories. I don't know why it didn't
happen simultaneously in biomedical science. Perhaps
it was because the academic people felt that any
connection to industry and the marketplace would
somehow contaminate them and lead them away
from their primary objective of understanding the
mechanisms of nature. I think, though, that the main
problem was that the two communities simply
existed apart from each other. They didn't go to the
same meetings, didn't belong to the same societies.
And the change has come about because there has
been a revolution in science in the academic world. It
became clear to everybody that there would be
practical applications of this new science, and the
corporate world was interested.
But it should also be said that the university world
no longer has a feeling of apprehension about intellectual contact with the corporate world. I could cite
the Hoechst contract with Massachusetts General
Hospital that provides a large sum of money over 20
years to support pure basic research in molecular
genetics. There is no requirement that the Harvard
scientists in the Mass. General laboratories choose a
line of research that would be of special interest to a
pharmaceutical house, much less any obligation to
produce a product. The only quid pro quo I'm aware
of is that the corporation gets the first look at the
basic science as it comes out, and if it looks interesting
they have the first option to turn it into a product.
There are similar arrangements between Du Pont
and the Harvard Medical School, as well as Johnson
and Johnson and the Scripps Clinic and Research
Foundation in California—plus a good many others
now on-line. Now, I can't imagine that such a
partnership with industry could ever cover more than
10 percent of a lab's research costs, but what it does
is provide long-term support that the government
doesn't provide. Government support comes in twoyear awards from the National Institutes of Health
(NIH), and the young investigators feel these days
that they are in a very unstable environment if they
depend entirely on NIH grants. In fact, there has been
a recent tendency to take on research problems that
look absolutely sound and which promise results
within 12 to 18 months. So the new arrangements
with industry mean that the investigators don't need
to be apprehensive about their salaries and can
undertake longer-term approaches to research. And
the ability to gamble in the laboratory is what has
made American science the best science on earth.

with these

Science, you're saying, is built on
thinking.

new

long-range

Not in research itself, not at all. Basic research is done
by people who want quick answers to engrossing
questions. But they are also aware of two other
things. First, your original guess is probably going to
turn out to be wrong. You can write a 100-page
application to NIH saying exactly what you're going
to do the next two years; but if you're a good investigator, you'll put that aside as soon as you start,
because you're going to notice things you hadn't
expected to see and soon find yourself in a different
world. The second lesson is that you never finish. As
soon as you reach what you think is the final answer
to a problem, it stops becoming a final answer and
becomes an array of new questions. So in that sense
you could say it is long-range thinking.
Who has changed, then, the basic scientist or
the applied scientist, as they now work together?
Well, it comes back to both sides realizing that you're
not going to get any applied science solutions falling
into your lap without a lot of basic inquiry happening
beforehand. I think we in the academic world have
tended to look down our noses at industrial science in
the past as not pure science but just a way of
making money. And now there are some very
amiable and exciting relationships beginning to start
up between these two scientific worlds; and, if
handled carefully, this could be a wonderful thing for
our country. It could put us in a better competitive
position with both Europe and Japan, where there's a
closer connection between applied and basic science.
What do you mean, handled

carefully?

There is anxiety in the university world over the issue
of confidentiality and secrecy—that the needs for
patents and licensing will delay information coming
out of the basic research laboratory. But I think that if
the information is patentable, it will not take all that
time to get the machinery cranked up. So I don't see
a restraint on publication. What I am worried about
is that there may be less free gossiping in the halls of
university science. When the bright investigators I
know run into something interesting in their lab, they

can't wait until lunch time to tell everyone else. And
this communication system based on phone calls,
corridor gossip, and international meetings is very
effective. So I worry that investigators may think that
if they tell what is going on in their laboratory,
someone else may pick it up, and they'll lose their
priority on it. It's not something to worry about now,
but we should be apprehensive about it in the future.
Do you think the public understands
basic science
works?

how

No. In fact, I think the public worries about what
scientists may be doing to the world. They associate
technology—such as for thermonuclear weapons—
with science much more closely than they should.
Technology is one thing, and science is another.
Society, through its elected officials, certainly ought to
choose between what technology it wants and what it
doesn't want; but, as I said, you can't make choices in
basic science. There aren't any questions that should
be disallowed, because you can't predict how the
inquiry is going to turn out.
Even when there is apprehension,
concerning genetic
engineering?

such as that

Well, we've had a long run now in molecular genetics
—almost 10 years—since the scientists themselves first
cited the possible dangers of gene transfers. So there
was a moratorium for a while, and a lot of guidelines
were established by the NIH which are still in effect;
and there's been no evidence of any accident, not even
of any risk. Quite clearly, nothing has gone wrong.
There's a general agreement now within the scientific
community that such research applications as interferon and the cloning of genetic information essentially carry no risk at all. But there is still a feeling in
the public mind that fooling around with the genome
is something we ought not to be doing.
The

genome?

That's jargon for the entire genetic machinery in the
nucleus of the cells. The interest, you see, lies in
replacing DNA that may be congenitally lacking in
cells; for when it is, some people don't have the right
enzymes that are essential for life. And while it can't
be done now, replacing that DNA information
sometime in the future could save the lives of children
who -would otherwise die. But I don't think this socalled genetic engineering will ever be applied to the
germ plasm itself.
Out of choice or the lack of

technology?

Both. It's a complicated ethical question, really, and I
don't see much interest in the scientific community to
go ahead with this kind of work. I can't imagine
anybody in science ever -wanting to become involved
in the cloning of a human being, for example, even if
one day it could be done. Besides, it would require
the whole GNP just to support the research, because
you'd have to clone parents, grandparents, aunts,
uncles, cousins—the entire environment—and that's a

science fiction invention. I think that what is needed
is a better case made by the scientific community for
what is going on in basic research. The main thing
that is happening is that we're beginning to understand how life works. When people look back at the
twentieth century, the most important discovery of
science may be that we learned how little we know
about our origins, about how our minds -work, and
how we live together. In preceding centuries -we
thought we knew everything; in this century, we have
discovered through science how ignorant we are.
It sounds like there is a communications
gap
here. Is it not difficult for science to
communicate its potential to the public?
Yes, and one of my preoccupations these days is to
help the general literate public understand what is
going on in science. So I am helping to develop a
series of books by -working scientists. They will be on
everything from galactic cosmology to molecular
genetics. What happened, for example, during that
major portion of the earth's existence up to a billion
years ago when there was nothing but bacteria and
perhaps their viruses? Biological habits originated
then that have persisted. Another subject is clinical
science. How do you actually do research with human
patients? What are the objectives? What ethical
problems exist?
Are there going to be certain
scientific
discoveries down the road that confront us with
ethical
decisions?
We scientists may have to confront some ethical
choices. For example, there's something about cloning
individuals that I myself find a plain violation of the
human spirit—it would be wrong. I would take a
stand that it should be forbidden. But even in that case
it would not be science itself that would raise the
ethical question; it would be the application of the
science that would do so. Let's take a more realistic
possibility—that we -will be able to transplant human
organs with ease. That also is technology, and
-whether or not to spend money on basic science to
make that possible should be a public decision. It
should not be a decision made by doctors or biomedical scientists. It should be made by Congress and
the people.
Would you sum up your thoughts about the
basic and applied sciences, and the role of
research in our society?
We are an industrial society, and the whole -world is
becoming one as -well. If we are going to be successful
in developing the technologies that we need in order
to survive as a species, we need to be totally dependent on basic research. The topmost priority in the
United States of America ought to be the fostering of
a fundamental inquiry into nature, without imposing
targets, without trying to choose between fields.
Research in marine biology should be just as important as research on human DNA, and that extends to
laser communications, to artificial intelligence, to all
physics, chemistry, and the biological sciences. I think
we can afford it. I know we're good at it, and we
ought to be enlisting our brightest young people to do
it. I think the future depends on it.
&

